Irsogladine is a gastroprotective agent.1,2,3 It increases transfer of Lucifer yellow CH between isolated rabbit gastric epithelial cells, indicating enhanced gap junction intercellular communication (GJIC).2 Irsogladine (3 mg/kg) inhibits gastric mucosal lesion formation and decreases in gastric mucosal blood flow induced by monochloramine in rats, effects that can be prevented by the nitric oxide synthase inhibitor L-NAME .1 It also inhibits superoxide anion production induced by fMLP and increases cAMP levels in isolated human neutrophils in a concentration-dependent manner, similar to the phosphodiesterase 4 (PDE4) inhibitor rolipram .3
1.Kyoi, T., Oka, M., Noda, K., et al.Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in ratsJ. Pharmacol. Sci.93(3)314-320(2003) 2.Ueda, F., Ban, K., and Ishima, T.Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptorJ. Pharm. Exp. Ther.274(2)815-819(1995) 3.Kyoi, T., Noda, K., Oka, M., et al.Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophilsLife Sci.76(1)71-83(2004)